Abstract | BACKGROUND: OBJECTIVE: To review the current evidence from animal studies and randomised controlled trials on the therapeutic effect of PUFAs in MS. METHODS: RESULTS: There was some evidence from animal model studies indicating an effect of ω-6 PUFAs, while the results from randomised controlled trials (RCTs) indicated that the ω-6 PUFAs linoleic acid or γ- linolenic acid have no beneficial effects on clinical disease activity in MS. However, the identified studies had several limitations in design with a mixture of relapsing-remitting and progressive MS patients. No studies investigated ω-6 efficacy on MRI disease activity. For ω-3 PUFAs, there was conflicting results from animal studies. RCTs show no beneficial treatment effect of the ω-3 PUFAs eicosapentaenoic acid and docosahexaenoic acid on MRI or clinical disease activity in MS. CONCLUSION: Randomised controlled trials of PUFA intervention provide no evidence of beneficial effects from ω-3 or ω-6 PUFAs on relapse rate, disability progression or MRI disease activity in MS.
|
Authors | S Wergeland, Ø Torkildsen, L Bø, K-M Myhr |
Journal | Acta neurologica Scandinavica. Supplementum
(Acta Neurol Scand Suppl)
Issue 195
Pg. 70-5
( 2012)
ISSN: 1600-5449 [Electronic] Denmark |
PMID | 23278660
(Publication Type: Journal Article, Review)
|
Copyright | © 2012 John Wiley & Sons A/S. |
Chemical References |
|
Topics |
- Animals
- Dietary Supplements
- Disease Models, Animal
- Disease Progression
- Encephalomyelitis, Autoimmune, Experimental
(diet therapy)
- Fatty Acids, Unsaturated
(therapeutic use)
- Humans
- Multiple Sclerosis
(diet therapy)
|